Anti-TNF antibody, expressed in mammalian cell culture, 1330 residues, MW=148 kD. Humira was created using phage display technology resulting in an antibody with human derived heavy and light chain variable regions and human IgGl:K constant regions. It is produced by recombinant DNA technology in a mammalian cell expression system

Humira - Pharmacology:

Humira binds to TNF-alpha and blocks its interaction with the p55 and p75 cell surface TNF receptors. Humira also lyses surface TNF expressing cells in vitro in the presence of complement.

Humira Interactions


HUMIRA has been studied in rheumatoid arthritis patients taking concomitant MTX. The data do not suggest the need for dose adjustment of either HUMIRA or MTX.


Concurrent administration of anakinra (an interleukin-1 antagonist) and another TNF-blocking agent has been associated with an increased risk of serious infections, an increased risk of neutropenia and no additional benefit compared to these medicinal products alone. The safety and efficacy of anakinra used in combination with HUMIRA has not been studied. Therefore the, combination of anakinra with other TNF-blocking agents, including HUMIRA, may also result i n similar toxicities.

Humira Contraindications

HUMIRA should not be administered to patients with known hypersensitivity to HUMIRA or any of its components.

Generic name, Overdose, Half Life Humira, Food Interactions, Chemical, etc..

Humira see also FDA report